Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -1.19% 20.75 20.00 21.50 21.00 20.75 21.00 86,338 08:12:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.5 5.7 6.7 3.1 18

OptiBiotix Health PLC Publication of third human study on LPLDL

18/01/2022 7:00am

RNS Non-Regulatory


TIDMOPTI

OptiBiotix Health PLC

18 January 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Publication of third human study on LP(LDL) (R)

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, a nn o unces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has published a third human volunteer study on its cholesterol reducing probiotic, Lactobacilus plantarum ECGC13110402, branded as LP(LDL) (R).

Previous studies have shown that LP(LDL) (R) was safe and that the higher the starting level of cholesterol, the greater the cholesterol reduction. The aim of this study was to provide further data in a different population group of hypercholesterolemic adults (TC (3) 6mM). These subjects are most likely to benefit from a cholesterol reducing effect and the target population of greatest commercial interest group to partners exploring the potential of LP(LDL) (R)as an over the counter (OTC) natural consumer health product or drug biotherapeutic.

The study was a nine-week follow-up, single centre, double-blind, randomised, placebo controlled human intervention study. Participants were randomly assigned to one of two treatments, active (4x10(9) CFU LP(LDL) (R) /day) or placebo. Treatment duration was six weeks, focusing on the time points whereby significant changes occurred in the original study, followed by a three-week washout period.

The results showed that at six weeks, when volunteers taking placebo were compared to those taking LP(LDL) (R), there were statistically significant changes to clinically important cardiovascular risk including a:-

   --    34.2% reduction in total cholesterol (p=0.001) 
   --    28.4% reduction in LDL cholesterol (bad cholesterol) (p=0.03) 
   --    17.6% reduction in non-HDL-C (p =0.001) 
   --    28.6% reduction in apoB (p=0.008) 

No safety, compliance, or tolerance issues were reported by volunteers during the study. The results of this independent, blinded study provide further evidence of the ability of LP(LDL) (R)to improve clinically important cardiovascular risk factors in volunteers with high levels of cholesterol. These results suggest efficacy similar to many statins and treatments more typically associated with pharmaceuticals and a potential use for LP(LDL) (R)in:-

i. Individuals who have rising levels of cholesterol who have been advised by their clinician to make lifestyle changes to reduce their risk of coronary heart disease

ii. Individuals with raised levels of cholesterol who are statin intolerant or do not want to take statins for ethical or other medical reasons

iii. As a supplement to existing treatment which could allow a clinician to use a lower, better tolerated statin dose

Stephen O'Hara, CEO of OptiBiotix, commented: "We are really excited with the results of this study which

show statistically significant reductions in a number of clinically important cardiovascular risk factors with no compliance, tolerance, or safety issues. These results, along with previous studies and customer feedback, suggest a potential role in the use of probiotics like LP(LDL) (R) in individuals who have high levels of cholesterol who are unwilling or unable to tolerate existing treatments. Given the market opportunity and possible limitations of existing treatments, the commercial potential for LP(LDL) (R) in isolation or in combination with existing approaches looks promising."

For further information, please contact:

 
 OptiBiotix Health plc                      www.optibiotix.com 
 Stephen O'Hara, Chief Executive          Contact via Walbrook 
                                                         below 
 
 
 Cenkos Securities plc (Broker)             Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                            Mob: 07876 741 001 
 Anna Dunphy 
 
 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPUUCGUPPGMM

(END) Dow Jones Newswires

January 18, 2022 02:00 ET (07:00 GMT)

1 Year Optibiotix Health Chart

1 Year Optibiotix Health Chart

1 Month Optibiotix Health Chart

1 Month Optibiotix Health Chart
ADVFN Advertorial
Your Recent History
LSE
OPTI
Optibiotix..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220625 16:24:05